Abstract P1-14-07: Randomized phase 3 study of anthracycline-containing regimens versus S-1 as first-line treatment for metastatic breast cancer (SELECT BC-CONFIRM)–A combined analysis of two randomized phase 3 studies (SELECT BC-CONFIRM and SELECT BC)–

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Phase 3 ◽

Combined Analysis ◽

Faculty of 1000 evaluation for Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717976445.793471388 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments

BMC Cancer ◽

10.1186/1471-2407-13-164 ◽

2013 ◽

Vol 13 (1) ◽

Cited By ~ 15

Author(s):

Lucia Del Mastro ◽

Alessandra Fabi ◽

Mauro Mansutti ◽

Michele De Laurentiis ◽

Antonio Durando ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Trial ◽

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)30154-1 ◽

2016 ◽

Vol 17 (9) ◽

pp. 1230-1239 ◽

Cited By ~ 22

Author(s):

Christoph Zielinski ◽

István Láng ◽

Moshe Inbar ◽

Zsuzsanna Kahán ◽

Richard Greil ◽

...

Keyword(s):

Breast Cancer ◽

Primary Endpoint ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer

PLoS ONE ◽

10.1371/journal.pone.0227256 ◽

2020 ◽

Vol 15 (4) ◽

pp. e0227256

Author(s):

Cynthia Huang Bartlett ◽

Jack Mardekian ◽

Matthew James Cotter ◽

Xin Huang ◽

Zhe Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Real World ◽

Metastatic Breast ◽

Progression Free Survival ◽

Line Treatment ◽

First Line ◽

Phase 3 ◽

Free Survival ◽

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70439-5 ◽

2014 ◽

Vol 15 (11) ◽

pp. 1269-1278 ◽

Cited By ~ 82

Author(s):

Gunter von Minckwitz ◽

Fabio Puglisi ◽

Javier Cortes ◽

Eduard Vrdoljak ◽

Norbert Marschner ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Second Line ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Locally Recurrent ◽

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

The Lancet Oncology ◽

10.1016/s1470-2045(12)70566-1 ◽

2013 ◽

Vol 14 (2) ◽

pp. 125-133 ◽

Cited By ~ 59

Author(s):

Istvan Lang ◽

Thomas Brodowicz ◽

Larisa Ryvo ◽

Zsuzsanna Kahan ◽

Richard Greil ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Exemestane and Chemotherapy as First-line Treatment of Metastatic Breast Cancer: Results of a Phase II Study

Clinical Breast Cancer ◽

10.3816/cbc.2010.n.041 ◽

2010 ◽

Vol 10 (4) ◽

pp. 313-317 ◽

Cited By ~ 3

Author(s):

Juan de la Haba-Rodriguez ◽

Rosario González Mancha ◽

Gumersindo Pérez Manga ◽

Enrique Aranda Aguilar ◽

José Manuel Baena Cañada ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study

BMC Research Notes ◽

10.1186/1756-0500-5-162 ◽

2012 ◽

Vol 5 (1) ◽

Cited By ~ 2

Author(s):

Lamiaa Boulaamane ◽

Saber Boutayeb ◽

Hassan Errihani

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-013-2082-4 ◽

2013 ◽

Vol 71 (4) ◽

pp. 913-919 ◽

Cited By ~ 16

Author(s):

Hesham Tawfik ◽

Yousri Rostom ◽

Hesham Elghazaly

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer

Annals of Oncology ◽

10.1093/annonc/mdq122 ◽

2010 ◽

Vol 21 (12) ◽

pp. 2305-2315 ◽

Cited By ~ 23

Author(s):

A. Chan ◽

D.W. Miles ◽

X. Pivot

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽